Satori Pharmaceuticals is developing life-changing therapeutics for Alzheimer's disease. Driven by a world-class team of drug development veterans and advisors, Satori is advancing best-in-industry medicines that aim to slow or stop disease progression. Our drug candidates selectively modulate gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques - the signature of this debilitating disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/23/12 | $15,000,000 |
InterWest Partners Prospect Venture Partners | undisclosed |
